Advertisement: RSM
RealVNC mid-banner general
Advertisement EY mid banner
Advertisement: Wild Knight Vodka
Advertisement: TTP
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
RealVNC mid banner careers
Mid banner advertisement: BDO
Advertisement: Mogrify
Advertisement: Cambridge Network
Advertisement: Innova Systems
22 January, 2020 - 21:19 By Kate Sweeney

Novacyt subsidiary hits French aquaculture market

Cambridge clinical diagnostics business Novacyt reports that its molecular testing division, Primerdesign, has gained a foothold in the growing French aquaculture and aquamarine markets.

The breakthrough deal is with Atothis SARL, part of VGS Invest Holding Sarl Group, for the distribution of certain molecular diagnostic products in the sector.

France is the second largest aquaculture producer in the EU, with shellfish production alone contributing a total of 155,000 tonnes a year valued at approximately €550 million to the French economy.

The distribution partnership combines the commercial strength of the VGS Group, with Primerdesign’s innovative molecular genesig® diagnostic tests and the company’s proprietary q16 instrument.

Primerdesign’s diagnostic products will be used for the early identification of diseases impacting animal health during food production.

The agreement has an initial term of three years and commits VSG to buy a minimum of €690,000 of Primerdesign products.

The VGS Group, which trades as Antinea, is the largest independent distributor of aquamarine products in France. Antinea was founded in 1991 and has grown significantly. It employs over 70 personnel dedicated to the French market.

Valery Perinet, CEO of the VGS Group, said: “After evaluating the extensive Primerdesign product range we are convinced this partnership will create significant value for both companies in a market which is growing rapidly.”

Graham Mullis, group CEO of Novacyt, added: “As the largest independent aquamarine distributor in France, VGS Group is an ideal partner for Novacyt in this growing area.

“In addition, as a leading aquaculture producer in the EU, France represents a significant market opportunity for Novacyt. This important agreement reinforces our previously identified organic growth strategy, which includes focusing on strategic partners in the animal testing market.

“We continue to focus on making our extensive range of molecular products available to multiple markets through the appointment of strategic partners in key territories. I look forward to updating the market with additional partnerships as we expand our sales channels.”

Newsletter Subscription

Stay informed of the latest news and features